| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/NYAS.12824 |
| P8608 | Fatcat ID | release_t4uh4gl4ijdvzel65m3qzg4xxa |
| P698 | PubMed publication ID | 26200808 |
| P50 | author | Scott M Whitcup | Q96337420 |
| P2093 | author name string | Michael R Robinson | |
| P2860 | cites work | Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study | Q34305621 |
| Uveitis: a potentially blinding disease. | Q35838711 | ||
| Risks of intravitreous injection: a comprehensive review | Q35922099 | ||
| Immunosuppression for posterior uveitis | Q36012275 | ||
| Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts | Q36124980 | ||
| The impact of macular edema on visual function in intermediate, posterior, and panuveitis. | Q36814725 | ||
| Triamcinolone acetonide in ocular therapeutics | Q36919110 | ||
| Causes and frequency of blindness in patients with intraocular inflammatory disease | Q37319691 | ||
| Biodegradable implants for sustained drug release in the eye. | Q37763871 | ||
| The gold standard of noninfectious uveitis: corticosteroids. | Q38003879 | ||
| Intraocular corticosteroids for posterior segment disease: 2012 update | Q38025444 | ||
| Sterile endophthalmitis after intravitreal injections | Q38042910 | ||
| Intraocular pressure monitoring post intravitreal steroids: a systematic review | Q38114592 | ||
| Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. | Q38218369 | ||
| Side-effects of anti-inflammatory therapy in uveitis. | Q38261127 | ||
| Normative comparison of patient-reported outcomes in patients with noninfectious uveitis | Q38456029 | ||
| Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis | Q38495949 | ||
| Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema | Q42165531 | ||
| Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. | Q43086468 | ||
| Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography | Q44879359 | ||
| Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. | Q45133527 | ||
| Particle-induced endophthalmitis: possible mechanisms of sterile endophthalmitis after intravitreal triamcinolone | Q45173967 | ||
| Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome | Q46096633 | ||
| Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema | Q46338042 | ||
| Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis | Q46500358 | ||
| Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis | Q46505357 | ||
| Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency | Q48597818 | ||
| Referral patterns of uveitis in a tertiary eye care center. | Q51034605 | ||
| Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. | Q53582817 | ||
| Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis | Q57638942 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | uveitis | Q280027 |
| dexamethasone | Q422252 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2015-07-22 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis | |
| P478 | volume | 1358 |
| Q30376710 | Calcium Phosphate as a Key Material for Socially Responsible Tissue Engineering. |
| Q47917078 | Hyaluronic Acid Graft Copolymers with Cleavable Arms as Potential Intravitreal Drug Delivery Vehicles |
| Q97530818 | Identifying Specific Combinations of Matrix Properties that Promote Controlled and Sustained Release of a Hydrophobic Drug from Electrospun Meshes |
| Q92003402 | Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial |
| Q60921071 | Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world |
| Q53821073 | Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: A case series. |
| Q90728348 | Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice |
| Q60306241 | Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis |
| Q38834085 | Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment |
| Q58608160 | Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery |
| Q53829701 | The effects of repeated Ozurdex injections on ocular hypertension. |
Search more.